{"nctId":"NCT02104830","briefTitle":"Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients","startDateStruct":{"date":"2013-09"},"conditions":["Chemotherapy-induced Neutropenia"],"count":135,"armGroups":[{"label":"Empegfilgrastim 6 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Empegfilrastim 6 mg","Biological: Placebo №2"]},{"label":"Empegfilgrastim 7.5 mg","type":"EXPERIMENTAL","interventionNames":["Biological: Placebo №2","Biological: Empegfilrastim 7.5 mg"]},{"label":"Filgrastim","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Filgrastim","Biological: Placebo №1"]}],"interventions":[{"name":"Empegfilrastim 6 mg","otherNames":["Extimia","metpegfilgrastim","pegylated filgrastim","peg-GCSF"]},{"name":"Filgrastim","otherNames":["GCSF"]},{"name":"Placebo №1","otherNames":[]},{"name":"Placebo №2","otherNames":[]},{"name":"Empegfilrastim 7.5 mg","otherNames":["Extimia","metpegfilgrastim","pegylated filgrastim","peg-GCSF"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent form;\n* Histologically verified diagnosis of stage IIb/III/IV breast cancer;\n* Age of 18-70 years inclusive;\n* Life expectancy of at least 6 months after inclusion in the study;\n* If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;\n* ECOG Performance Status of 0- 2, not increasing within during 2 weeks before randomization;\n* ANC level of 1500/μL and more at the beginning of the study\n* Platelet count of 100 000/μL and more at the beginning of the study\n* Hemoglobin level of 90 g/l and more\n* Creatinine level \\<1.5 mg/dl\n* Total bilirubin level \\<1.5 × the upper limit of normal (ULN)\n* ALT and/or AST levels \\<2.5×ULN (5×ULN for patients with liver metastases);\n* Alkaline phosphatase \\<5×ULN;\n* Left ventricular ejection fraction \\>50% and more;\n* If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin,if in this study planned 6 cycles of chemotherapy ;\n* If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for epirubicin,if in this study planned 4 cycles of chemotherapy ;\n* Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;\n* Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug;\n* Patients should be able to follow the Protocol procedures (according to Investigator's assessment.\n\nExclusion Criteria:\n\n* Patient has received two or more chemotherapy regimens for the metastatic breast cancer;\n* Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.\n* Pregnancy or breastfeeding;\n* Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;\n* Concomitant radiotherapy (except selective radiotherapy of bone metastases);\n* Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;\n* History of bone marrow/stem cell transplantation;\n* Conditions limiting the patient's ability to follow the protocol;\n* CTCAE grade 3-4 neuropathy;\n* HIV, HCV, HBV, T.Pallidum infection(s);\n* Acute or active chronic infections;\n* Severe concurrent diseases (for example, severe arterial hypertension, severe heart failure, and other);\n* Severe depression, schizophrenia, any other mental disorders;\n* Obstacles in intravenous administration of study drugs;\n* Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Neutropenia CTCAE Grade 4","description":"The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.905","spread":"1.206"},{"groupId":"OG001","value":"0.791","spread":"1.013"},{"groupId":"OG002","value":"1.725","spread":"1.519"}]}]}]},{"type":"SECONDARY","title":"The Duration of Grade 4 Neutropenia From the 2nd (Week 6) to 4th Cycle (Week 12);","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.452","spread":"1.194"},{"groupId":"OG001","value":"0.326","spread":"0.919"},{"groupId":"OG002","value":"0.925","spread":"1.385"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.244","spread":"0.734"},{"groupId":"OG001","value":"0.310","spread":"0.680"},{"groupId":"OG002","value":"0.641","spread":"0.932"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.195","spread":"0.601"},{"groupId":"OG001","value":"0.475","spread":"1.320"},{"groupId":"OG002","value":"0.892","spread":"1.197"}]}]}]},{"type":"SECONDARY","title":"The Incidence of Severe Neutropenia (Grade 3-4)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"34","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Low Level (Nadir) ANC x 10^9/L","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.68","spread":"0.68"},{"groupId":"OG001","value":"0.91","spread":"1.11"},{"groupId":"OG002","value":"0.47","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"1.30"},{"groupId":"OG001","value":"2.10","spread":"1.78"},{"groupId":"OG002","value":"0.87","spread":"1.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"1.39"},{"groupId":"OG001","value":"1.88","spread":"1.71"},{"groupId":"OG002","value":"0.94","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.67","spread":"1.12"},{"groupId":"OG001","value":"2.07","spread":"1.75"},{"groupId":"OG002","value":"0.75","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Neutropenia Duration, Any Grade","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.214","spread":"1.152"},{"groupId":"OG001","value":"1.953","spread":"1.194"},{"groupId":"OG002","value":"4.0","spread":"3.121"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.881","spread":"2.276"},{"groupId":"OG001","value":"1.233","spread":"1.702"},{"groupId":"OG002","value":"2.775","spread":"2.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.585","spread":"1.897"},{"groupId":"OG001","value":"1.024","spread":"1.199"},{"groupId":"OG002","value":"2.487","spread":"2.480"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.146","spread":"1.195"},{"groupId":"OG001","value":"1.525","spread":"2.364"},{"groupId":"OG002","value":"2.919","spread":"2.488"}]}]}]},{"type":"SECONDARY","title":"Duration From ANC Nadir to ANC < 2.0 x 10^9/L","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":"0.98"},{"groupId":"OG001","value":"1.51","spread":"0.86"},{"groupId":"OG002","value":"2.98","spread":"2.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"1.29"},{"groupId":"OG001","value":"1.05","spread":"1.31"},{"groupId":"OG002","value":"2.05","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.20","spread":"1.21"},{"groupId":"OG001","value":"0.98","spread":"0.90"},{"groupId":"OG002","value":"1.90","spread":"1.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.12","spread":"1.05"},{"groupId":"OG001","value":"1.03","spread":"1.20"},{"groupId":"OG002","value":"2.14","spread":"1.70"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":42},"commonTop":["Leucopenia","neutropenia any grade","Weakness / asthenia","Anemia","Hyperglycemia"]}}}